bullish
China Healthcare Weekly (Dec.24)- Capital Arbitrage, Drug Commercial Results, Healthcare Big Picture
334 Views27 Dec 2021 09:13
This insight analyzed the concerns on capital arbitrage in domestic innovative drugs, the unsatisfactory innovative drug commercial results, and bullish on China healthcare due to China's prosperity.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Jan.7)-China's Drug Spending,Logic Behind China/US Biotech, Anesthetics VBP09 Jan 2022
- The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector06 Jan 2022
- China Healthcare Weekly (Dec.31)-1st State-Level Device Policy,TCM Guideline,TCM Rally Unsustainable02 Jan 2022
- China Healthcare Weekly (Dec.24)- Capital Arbitrage, Drug Commercial Results, Healthcare Big Picture27 Dec 2021
- The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)20 Dec 2021
- China Healthcare Weekly (Dec.17)-The Most Important Policy in Next Three Years,Pacemaker VBP Results19 Dec 2021
- 2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties25 Nov 2021
x